COMP <GO>
SLS vs GENB // ENTERPRISE SCALE & MARKET CAP
SELLAS Life Sciences Group Inc. (NASDAQ) VS. Generate Biomedicines Inc. (NASDAQ) • 15-METRIC TALLY: SLS 1
— GENB 1
▲ ENTERPRISE SCALE & MARKET CAP LEADER: SLS
LAST: $10.15 (-2.17%) • MKT CAP: $2.05B
market-cap
$2.05B
LAST: $15.77 (+2.54%) • MKT CAP: $2.02B
market-cap
$2.02B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SLS VS. GENB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SLS | GENB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.80% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.38% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.7 | 52.8 | -14.09 | GENB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $2.05B | $2.02B | $26.6M | SLS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SLS REV | GENB REV | SLS GROSS % | GENB GROSS % | SLS FCF | GENB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$28.4M | — |
| FY 2024 | $0 | — | — | — | -$35.4M | — |
| FY 2023 | $0 | — | — | — | -$31.4M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SLS // BETA —
GENB // BETA —